CHICAGO--(BUSINESS WIRE)--The new leadership team at Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, has provided refreshed estimated, unaudited ranges of financial information for fiscal 2023. Dr. Shih-Yin Ho, Interim CEO, and Lee Westerfield, Interim CFO, will discuss Veradigm’s mission, business and operations, and innovation strategy, as well as its estimated financial information for fiscal 2023, at the J.P. Morgan Healthcare Conference on Wednesday, Januar ...

Providers using Veradigm EHRs to gain access to longitudinal patient records, improving interoperability and driving better treatment decisions FISHKILL, N.Y. and CHICAGO, Ill., Jan. 9, 2024 /PRNewswire/ -- MedAllies, a leading healthcare interoperability and connectivity services provider, announced today that Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology services, has selected MedAllies as its Qualified Health Information Network (QHIN) partner. The effort will enable ...

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ:MDRX). About the Investigation A securities class action has been filed in U.S. District Court in the Northern District of Illinois on behalf of purchasers of Veradigm common stock between February 26, 2021 and June 13, 2023, inclusive (the "Class Period"). The lawsuit asserts violations of the Securi ...

CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market. “Today’s announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio b ...

```markdown PART I. FINANCIAL INFORMATION [Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited consolidated financial statements, detailing financial position, performance, and cash flows, with notes Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $492,597 | $132,517 | | Total current assets | $810,770 | $761,342 | | Goodwill | $523,927 | $506,607 | | Long-term assets attributable to discontinued operations | $0 | $793,156 | | **Total assets** | **$1,690,659** | **$2,425,229** | | **Liabilities & Equity** | | | | Total current liabilities | $253,091 | $547,082 | | Long-term debt | $200,326 | $350,062 | | **Total liabilities** | **$513,636** | **$1,017,091** | | **Total stockholders' equity** | **$1,177,023** | **$1,408,138** | Consolidated Statements of Operations For the third quarter of 2022, revenue from continuing operations grew **5.0%** year-over-year to **$151.9 million**, with income from continuing operations at **$10.9 million** Q3 2022 vs Q3 2021 Performance (in thousands) | Metric | Q3 2022 | Q3 2021 | | :--- | :--- | :--- | | Total Revenue | $151,922 | $144,668 | | Gross Profit | $83,436 | $69,640 | | Income from Operations | $25,001 | $18,484 | | Income from Continuing Operations | $10,925 | $20,276 | | Net Income (Loss) | $14,528 | $16,180 | Nine Months 2022 vs 2021 Performance (in thousands) | Metric | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | | Total Revenue | $445,492 | $419,526 | | Gross Profit | $236,399 | $200,976 | | Income from Operations | $26,217 | $43,031 | | Income from Continuing Operations | $32,658 | $50,719 | | Net (Loss) Income | $(26,641) | $47,163 | Consolidated Statements of Cash Flows For the nine months ended September 30, 2022, net cash provided by operating activities was **$95.8 million**, a significant improvement from the **$140.5 million** used in the prior-year period Cash Flow Summary - Nine Months Ended Sep 30 (in thousands) | Cash Flow Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $95,767 | $(140,473) | | Net cash provided by (used in) investing activities | $603,719 | $(54,872) | | Net cash used in financing activities | $(387,374) | $(125,320) | | **Net increase (decrease) in cash** | **$311,384** | **$(321,145)** | Notes to Consolidated Financial Statements The notes provide detailed explanations of accounting policies and financial statement components, including convertible debt, revenue recognition, acquisitions, divestitures, and stock repurchases - Total unsatisfied performance obligations were **$989 million** as of September 30, 2022, with approximately **41%** expected to be recognized over the next 12 months[38](index=38&type=chunk) - The company acquired Babel Health for a net cash payment of **$24.5 million** on March 25, 2022, included in the Veradigm segment[57](index=57&type=chunk) - The company completed the sale of its Hospitals and Large Physician Practices Business for **$670.0 million** in cash, plus up to **$30.0 million** in contingent consideration, now reported as a discontinued operation[61](index=61&type=chunk) - The company repurchased **9.7 million shares** for **$177.0 million** under its 2022 stock purchase program during the nine months ended September 30, 2022[84](index=84&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and results of operations, highlighting key performance drivers and strategic impacts Overview of Consolidated Results For Q3 2022, total revenue increased **5.0%** to **$151.9 million**, and gross profit rose **19.8%** to **$83.4 million**, boosting gross margin to **54.9%** Q3 2022 vs Q3 2021 Financial Summary (in thousands) | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Total Revenue | $151,922 | $144,668 | 5.0% | | Gross Profit | $83,436 | $69,640 | 19.8% | | Gross Margin % | 54.9% | 48.1% | - | | Income from Operations | $25,001 | $18,484 | 35.3% | | Net Income (Loss) | $14,528 | $16,180 | (10.2%) | - SG&A expenses increased **18.7%** in Q3 2022, primarily due to higher legal costs and full recognition of corporate expenses previously allocated to the divested business[154](index=154&type=chunk) - Interest expense decreased **65.6%** in Q3 2022 due to lower debt levels and the adoption of ASU 2020-06 for convertible notes[158](index=158&type=chunk)[159](index=159&type=chunk) Segment Operations Following the divestiture of the Hospitals and Large Physician Practices business, the company's operations are now primarily focused on the Veradigm segment Veradigm Segment Performance - Q3 2022 vs Q3 2021 (in thousands) | Metric | Q3 2022 | Q3 2021 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $145,391 | $137,169 | 6.0% | | Gross Profit | $78,801 | $65,696 | 19.9% | | Income from Operations | $27,707 | $17,099 | 62.0% | | Operating Margin % | 19.1% | 12.5% | - | - Veradigm's gross profit and margin increased due to higher revenues, lower contractor usage, and improved hosting infrastructure costs[177](index=177&type=chunk) Liquidity and Capital Resources The company's liquidity position is strong, with cash and cash equivalents of **$494 million** and available borrowing capacity of **$699 million** as of September 30, 2022 - Principal liquidity sources as of September 30, 2022, include **$494 million** in cash and cash equivalents and **$699 million** available under the Revolving Facility[183](index=183&type=chunk) Cash Flow Summary - Nine Months Ended Sep 30, 2022 (in thousands) | Activity | Amount | | :--- | :--- | | Net cash provided by operating activities | $95,767 | | Net cash provided by investing activities | $603,719 | | Net cash used in financing activities | $(387,374) | - Future material cash requirements include **$207.9 million** for convertible senior notes, **$19.7 million** for operating leases, and **$38.3 million** in purchase obligations[192](index=192&type=chunk)[193](index=193&type=chunk)[194](index=194&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that there have been no material changes to its market risk disclosures during the nine months ended September 30, 2022 - Market risk disclosures have not changed materially during the nine months ended September 30, 2022[200](index=200&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of September 30, 2022 - The CEO and CFO concluded that disclosure controls and procedures were effective as of September 30, 2022[202](index=202&type=chunk) - No material changes occurred in internal control over financial reporting during Q3 2022[204](index=204&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) This section details ongoing legal contingencies, including civil investigative demands and a settlement related to a deferred prosecution agreement - The company is subject to a civil investigative demand (CID) related to Horizon Clinicals software, with McKesson indemnifying Allscripts for related government payments and defense[115](index=115&type=chunk) - Practice Fusion settled a claimed breach of its Deferred Prosecution Agreement with the U.S. Attorney's Office for **$200,000**, extending the agreement by 11 weeks[116](index=116&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) The company reports no material changes to the risk factors previously disclosed in its Annual Report on Form 10-K - No material changes occurred from the risk factors previously disclosed in the company's Form 10-K[207](index=207&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section discusses the company's stock repurchase activity under its 2022 program, detailing shares repurchased and remaining authorization Stock Repurchase Activity - Q3 2022 | Period (2022) | Total Shares Purchased (thousands) | Average Price Paid Per Share | Total Cost (thousands) | | :--- | :--- | :--- | :--- | | July | 0 | $0.00 | $0 | | August | 1,476 | $17.28 | $25,494 | | September | 481 | $16.87 | $8,126 | | **Total Q3** | **1,957** | **$17.18** | **$33,620** | - Approximately **$73.2 million** remained available for purchase under the 2022 stock repurchase program as of September 30, 2022[210](index=210&type=chunk) [Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including various agreements, CEO and CFO certifications, and Inline XBRL data files ```

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Richard Poulton - CEO Thomas Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Charles Rhyee - Cowen and Company Thomas Keller - RBC Capital Markets George Hill - Deutsche Bank Cynthia Motz - Goldman Sachs Eric Percher - Nephron Research Operator Greetings, and welcome to A ...

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jenny Gelinas - VP, IR Rick Poulton - CEO Tom Langan - President and Chief Commercial Officer Leah Jones - CFO Conference Call Participants Stephanie Davis - SVB Securities Cindy Motz - Goldman Sachs Charles Rhyee - Cowen Sean Dodge - RBC Capital Michael Cherny - Bank of America George Hill - Deutsche Bank Jeff Garro - Piper Stanley Dolph Warburton - Nephron Research Operator L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4392754 (State or Other Jurisdiction of Incorporation or Organi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-4392754 (State or Other Jurisdiction of Incorporation or Organ ...

Financial Data and Key Metrics Changes - The company reported strong year-over-year growth in revenue, gross profit, and adjusted EBITDA, with an overall improvement in margins, earnings per share, and free cash flow [18][24][25] - Consolidated non-GAAP EPS was $0.13 per share, reflecting a 63% increase year-over-year [25] - Free cash flow from continuing operations was $35 million, with $25 million in free cash flow generated [26] Business Line Data and Key Metrics Changes - The Veradigm business segment saw a year-over-year revenue growth of 8% during the quarter [18] - Veradigm non-GAAP gross margin was 52.2%, up 420 basis points year-over-year [21] - Adjusted EBITDA for Veradigm grew 24% year-over-year, resulting in an adjusted EBITDA margin of 25.8%, an increase of 330 basis points year-over-year [24] Market Data and Key Metrics Changes - The Veradigm provider platform added over 500 new practices and 6,100 prescribing physicians during the quarter [19] - The U.S. Department of State selected the company's practice management platform for deployment to over 200 health units globally [19] Company Strategy and Development Direction - The company is focusing on the Veradigm business following the sale of its Hospital Large Physician Practices segment, aiming for continued success and growth opportunities [5][13] - There is potential for future acquisitions to augment organic growth, but the immediate focus remains on organic growth [57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining the revenue growth outlook for Veradigm at 6% to 7% year-over-year and adjusted EBITDA growth of 10% to 15% [29] - The company anticipates generating consolidated free cash flow from continuing operations in the range of $110 million to $120 million for the year [29] Other Important Information - The company amended its credit agreement to extend the maturity of the facility for an additional five years and secured improved pricing [28] - The results of the Hospital & Large Physician Practices business segment are reported as discontinued operations [14] Q&A Session Summary Question: Free cash flow guidance for Veradigm - Management clarified that the guidance reflects the consolidated entity and is indicative of steady-state operations [34][35] Question: Margins comparison between payer and life sciences - Management indicated that gross margins between provider and payer/life sciences are comparable, with improvements expected from operating leverage [37][38] Question: Revenue growth expectations for payer and life sciences - Management noted seasonality in the payer and life sciences segment but remains confident in achieving growth expectations later in the year [45][46] Question: Impact of early-stage biotech funding slowdown - Management stated there has been no significant impact from early-stage biotech funding issues, as their focus is on larger pharma companies [66] Question: Veradigm Touchpoint Media business growth - Management confirmed that the media business is expected to grow significantly, contributing to the overall growth of the payer and life sciences segment [73] Question: Net debt clarification - Management advised to add $68 million of cash to the balance sheet to arrive at the correct net debt figure, estimating it around $230 million [76]